Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics develops therapies intended to address underlying causes of heart disease, with a clinical-stage pipeline led by TN-201 and TN-401 gene therapies. TN-201 is an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Company news commonly covers clinical data from the MyPEAK-1 and RIDGE-1 studies, financial results, cardiovascular research collaborations, and preclinical work supporting TN-301, a highly selective HDAC6 inhibitor studied for heart failure and related cardio/muscular disease. Updates also reference Tenaya’s target identification and validation capabilities, including iPSC-derived cardiomyocytes, engineered heart tissue models and in vivo disease models.
Tenaya Therapeutics (NASDAQ:TNYA) granted stock options to new employees under its 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The company granted options to purchase 1,650,000 shares of common stock to newly appointed CFO Eric Hyllengren and an aggregate of 187,200 shares to two new non-executive employees.
The options have a ten-year term and an exercise price of $0.8365 per share, equal to the closing price on July 13, 2026. Vesting occurs over four years, with 25% vesting on the one-year anniversary of hire and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.
Tenaya Therapeutics (NASDAQ:TNYA) appointed Eric Hyllengren as Chief Financial Officer effective July 13, 2026. He will lead financial strategy, capital allocation, investor relations and corporate development.
Hyllengren has over 20 years of biotech finance and strategy experience, including CFO roles at Zura Bio and Atara Biotherapeutics, where he executed more than $500 million in public financings. Tenaya also announced the planned Q3 2026 retirement of Hiro Higa, Senior Vice President, Finance, who will remain as a consultant to support a smooth transition.
Tenaya Therapeutics (NASDAQ:TNYA) reported interim MyPEAK-1 Phase 1b/2 data for TN-201 gene therapy in MYBPC3-associated HCM.
Seven patients received TN-201; six were evaluable and showed reductions in left ventricular mass, improved NYHA class, KCCQ scores, exercise capacity, and favorable biomarker trends. TN-201 was generally well tolerated with no dose-limiting toxicities. The EMA granted PRIME designation and the FDA accepted a pediatric indication into the RDEP process. Enrollment at 6E13 vg/kg continues and Tenaya plans further long-term data in 2H 2026 and regulatory updates by year end.
Tenaya Therapeutics (NASDAQ:TNYA) will report new interim data from Cohorts 1 and 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.
Management will host a webcast at 8:00 a.m. ET, accessible via the Investors section under “Events & Presentations,” with an archived replay available for about 30 days.
Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Jefferies Global Healthcare Conference 2026 in New York from June 2-4, 2026.
CEO Faraz Ali is scheduled to present on Thursday, June 4, 2026, at 3:10 p.m. ET, with live and archived webcasts available via Tenaya’s investor website.
Tenaya Therapeutics (NASDAQ:TNYA) reported positive interim data from Cohorts 1 and 2 of the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for PKP2-associated ARVC.
All six treated adults showed meaningful PVC burden reductions (mean 64%) with TN-401 well tolerated at 3E13 and 6E13 vg/kg and supported by biopsy evidence of cardiac transduction. TN-401 also received EMA PRIME designation.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q1 2026 results and a business update on May 6, 2026. Cash and cash equivalents were $80.9M as of March 31, 2026, and Tenaya expects funding into the second half of 2027 including a $10.0M upfront from an Alnylam collaboration. The company highlighted upcoming clinical readouts for TN-201 and TN-401, preclinical TN-301 DMD data, FDA Rare Pediatric and Orphan designations for TN-301, and expanded research with Alnylam with milestones up to $1.1B.
Tenaya Therapeutics (NASDAQ: TNYA) announced acceptance of multiple abstracts for ASGCT 2026, including a late-breaking oral presentation with new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial of TN-401 for PKP2-associated ARVC. The presentation will include one-year Cohort 1 results and early Cohort 2 safety, biopsy and efficacy data on May 15, 2026. Tenaya will also present two posters and plans a webcast conference call to review RIDGE-1 data.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q4 and full-year 2025 results, highlighted early clinical readouts for lead gene therapies TN-201 and TN-401, preclinical TN-301 data in DMD models, a multi-target research collaboration with Alnylam, and a December public offering raising net proceeds of $55.8M.
The company reported cash and marketable securities of $100.5M at year-end and expects resources plus an anticipated Alnylam upfront payment to fund operations into the second half of 2027.
Tenaya Therapeutics (NASDAQ: TNYA) presented preclinical data at MDA 2026 showing its selective HDAC6 inhibitor TN-301 improved muscle performance and corrected DMD cardiomyopathy drivers in vitro and in vivo. TN-301 restored mdx mouse muscle function to wild-type levels at 3 mg/kg and corrected human DMD iPSC-cardiomyocyte defects. A Phase 1 in healthy adults showed TN-301 was generally well tolerated without serious adverse events or dose-limiting toxicities. Tenaya plans to advance TN-301 toward Phase 2 clinical development, with HFpEF and DMD among prioritized indications.